<DOC>
	<DOCNO>NCT01925638</DOCNO>
	<brief_summary>The purpose study see difference way body absorbs distribute BAY86-9766 give alone combination ketoconazole , drug may affect much BAY86-9766 absorbed , distribute eliminate body</brief_summary>
	<brief_title>Effect Ketoconazole Pharmacokinetics Refametinib</brief_title>
	<detailed_description />
	<mesh_term>Ketoconazole</mesh_term>
	<criteria>Healthy male subject Age : 18 45 year ( inclusive ) first screen examination / visit Body mass index ( BMI ) : 18.5 32 kg/mÂ² ( inclusive ) Ability understand follow studyrelated instruction . Subject , sexually active man surgically sterilize , must consent us condom intercourse ensures female partner practice adequate contraception , must willing refrain sexual intercourse begin trial ( sign inform consent ) 30 day last study drug administration Clinically significant disease condition Retinal pathology vien occlusion Left Ventricular ejection Fraction ( LVEF ) &lt; 60 % ( measure screening ) Multiple Gated Acquisition Scan ( MUGA ) echocardiogram</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Healthy Volunteers</keyword>
	<keyword>Refametinib</keyword>
	<keyword>Ketoconazole</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>